REDLAMP 3: Bortezomib-Based Therapy for Newly Diagnosed Mantle Cell Lymphoma

In a recent publication from the New England Journal of Medicine researchers presented results from an investigation into whether the substitution of bortezomib for vincristine in R-CHOP improved patient outcomes for patients newly diagnosed with mantle cell lymphoma. Mantle cell lymphoma is an unusual lymphoma that engenders much debate as to what treatments should be used in patient care. In the below video Dr. John Leonard discusses the efficacy of substituting bortezomib for vincristine in R-CHOP and how this could improve the outcomes in patients with newly diagnosed mantle cell lymphoma.

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

The previous entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

One thought on “REDLAMP 3: Bortezomib-Based Therapy for Newly Diagnosed Mantle Cell Lymphoma”

Post a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: